Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

  • Jean Claude ReubiEmail author
  • Beatrice Waser
Review Article


Peptide receptors have been found to represent excellent targets for in vivo cancer diagnosis and therapy. Recent in vitro studies have shown that many cancers can overexpress not only one but several peptide receptors concomitantly. One of the challenges for nuclear medicine in this field in the coming decade will be to take advantage of the co-expression of peptide receptors for multireceptor tumour targeting. In vitro receptor studies can reveal which peptide receptor is overexpressed in which tumour and which receptors are co-expressed in an individual tumour; such knowledge is a prerequisite for successful in vivo development. One group of tumours of particular interest in this respect is the neuroendocrine tumours, which have previously been shown often to express peptide receptors. This review summarises our investigations of the concomitant expression of 13 different peptide receptors, in more than 100 neuroendocrine tumours of the human intestine, pancreas and lung, using in vitro receptor autoradiography with subtype-selective ligands. The incidence and density of the somatostatin receptors sst1–sst5, the VIP receptors VPAC1 and VPAC2, the CCK1 and CCK2 receptors, the three bombesin receptor subtypes BB1 (NMB receptor), BB2 (GRP receptor) and BB3, and GLP-1 receptors were evaluated. While the presence of VPAC1 and sst2 was detected in the majority of these neuroendocrine tumours, the other receptors, more differentially expressed, revealed a characteristic receptor pattern in several tumour types. Ileal carcinoids expressed sst2 and VPAC1 receptors in virtually all cases and had CCK1, CCK2, sst1 or sst5 in approximately half of the cases; they were the only tumours of this series to express NMB receptors. Insulinomas were characterised by a very high incidence of GLP-1, CCK2 and VPAC1 receptors, with the GLP-1 receptors expressed in a particularly high density; they expressed sst2 in two-thirds and sst1 in approximately half of the cases and lacked CCK1 and NMB receptors. All gastrinomas had sst2 and GLP-1 receptors; they expressed GRP receptors in three-quarters of the cases and CCK1 or VPAC1 in approximately half of the cases. Most bronchial carcinoids had VPAC1, while sst1, sst2 and CCK2 were found in two-thirds of the cases and BB3 in one-third of the cases. These data provide evidence for the vast biological diversity of these neuroendocrine tumours. Moreover, the results represent a basis for starting and/or optimising the in vivo targeting of these tumours by selecting the suitable radiopeptides for tumour diagnosis and/or therapy. Finally, the data strongly encourage concomitant application of several radiopeptides to permit more efficient targeting of these tumours.


Peptide receptors Neuroendocrine tumours Tumour targeting Somatostatin 


  1. 1.
    Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PPM, Ausema L, Lameris JS, Reubi JC, Lamberts SWJ. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; I:242–244.Google Scholar
  2. 2.
    Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998; 351:417–418.PubMedGoogle Scholar
  3. 3.
    Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997; 57:1377–1386.PubMedGoogle Scholar
  4. 4.
    Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999; 59:1152–1159.PubMedGoogle Scholar
  5. 5.
    Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 1995; 36:1846–1853.PubMedGoogle Scholar
  6. 6.
    Virgolini I, Raderer M, Kurtaran A, Angelberger P, Yang Q, Radosavljevic M, Leimer M, Kaserer K, Li SR, Kornek G, Hübsch P, Niederle B, Pidlich J, Scheithauer W, Valent P. 123-I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 1996; 23:685–692.CrossRefPubMedGoogle Scholar
  7. 7.
    Behr TM, Jenner N, Behe M, Angerstein C, Gratz S, Raue F, Becker W. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999; 40:1029–1044.PubMedGoogle Scholar
  8. 8.
    Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G, Dierckx RA. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000; 27:1694–1699.PubMedGoogle Scholar
  9. 9.
    Reubi JC, Läderach U, Waser B, Gebbers J-O, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000; 60:3105–3112.PubMedGoogle Scholar
  10. 10.
    Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[d-Tyr(6), beta-Ala(11), Phe(13), Nle(14)] bombesin(6–14). Clin Cancer Res 2002; 8:1139–1146.PubMedGoogle Scholar
  11. 11.
    Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28:836–846.PubMedGoogle Scholar
  12. 12.
    Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996; 125:26–34.PubMedGoogle Scholar
  13. 13.
    Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. New York: Raven Press, 1995.Google Scholar
  14. 14.
    Lebtahi R, Le Cloirec J, Houzard C, Daou D, Sobhani I, Sassolas G, Mignon M, Bourguet P, Le Guludec D. Detection of neuroendocrine tumors:99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. J Nucl Med 2002; 43:889–895.Google Scholar
  15. 15.
    Reubi JC, Gugger M, Waser B. Coexpressed peptide receptors in breast cancers as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med 2002; 29:855–862.Google Scholar
  16. 16.
    Wank SA. Cholecystokinin receptors. Am J Physiol 1995; 269:G628–G646.PubMedGoogle Scholar
  17. 17.
    Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998; 50:265–270.PubMedGoogle Scholar
  18. 18.
    Kroog GS, Jensen RT, Battey JF. Mammalian bombesin receptors. Med Res Rev 1995; 15:389–417.PubMedGoogle Scholar
  19. 19.
    Hoyer D, Epelbaum J, Feniuk W, Humphrey PPA, Meyerhof W, O'Caroll AM, Patel Y, Reisine T, Reubi JC, Schindler M, Schonbrunn A, Taylor JE, Vezzani A. Somatostatin receptors. In: Girdlestrom D, ed. The IUPHAR compendium of receptor characterization and classification. London, UK: IUPHAR Media; 2000:354–364.Google Scholar
  20. 20.
    Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994; 107:1848–1855.PubMedGoogle Scholar
  21. 21.
    Palacios JM, Dietl MM. Regulatory peptide receptors: visualization by autoradiography. Experientia 1987; 43:750–761.PubMedGoogle Scholar
  22. 22.
    Reubi JC, Gugger M, Waser B, Schaer JC. Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001; 61:4636–4641.PubMedGoogle Scholar
  23. 23.
    Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP. [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001; 28:1319–1325.PubMedGoogle Scholar
  24. 24.
    Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler M, Bussolati G. Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 2000; 9:47–57.PubMedGoogle Scholar
  25. 25.
    Janson ET, Stridsberg M, Gobl A, Weslin J-E, Oeberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998; 58:2375–2378.PubMedGoogle Scholar
  26. 26.
    Reubi JC, Kappeler A, Waser B, Laissue JA, Hipkin RW, Schonbrunn A. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 1998; 153:233–245.PubMedGoogle Scholar
  27. 27.
    Reubi JC, Schaer JC, Waser B, Hoeger C, Rivier J. A selective analog for the somatostatin receptor subtype sst1 expressed by human tumors. Eur J Pharmacol 1998; 345:103–110.CrossRefPubMedGoogle Scholar
  28. 28.
    Reubi JC, Eisenwiener KP, Rink H, Waser B, Macke HR. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002; 456:45–49.CrossRefPubMedGoogle Scholar
  29. 29.
    Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 1995; 80:2806–2814.Google Scholar
  30. 30.
    Reubi JC, Waser B, Laissue JA, Gebbers J-O. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res 1996; 56:1922–1931.PubMedGoogle Scholar
  31. 31.
    Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, Reubi JC, Maina T. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med 2003; 30:247–258.Google Scholar
  32. 32.
    Scopinaro F, Varvarigou A, Ussof W, De Vincentis G, Archimandritis S, Evangelatos G, Corleto V, Pulcini A, Capoccetti F, Remediani S, Massa R. Breast cancer takes up99mTc bombesin. A preliminary report. Tumori 2002; 88:S25–S28.PubMedGoogle Scholar
  33. 33.
    Gotthardt M, Fischer M, Baltes N, Brandt D, Welcke U, Göke BM, Joseph K. Scintigraphic detection of insulinomas by [123I]-Exendin4[Y39] in a rat tumor model. J Nucl Med 2000; 41 Suppl 5:9P.Google Scholar
  34. 34.
    de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, van Gameren A, Krenning EP. Tumor response after [90Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001; 42:1841–1846.PubMedGoogle Scholar
  35. 35.
    Schmitt HS, Wild D, Ginj M, Reubi JC, Waser B, de Jong M, Bernard BF, Krenning EP, Mäcke HR. DOTA-NOC, a high affinity ligand of the somatostatin receptor subtypes 2, 3 and 5 for radiotherapy. J Labelled Cpd Radiopharm 2001; 44 Suppl 1:S697–S699.Google Scholar
  36. 36.
    Soll RM, Dinger MC, Lundell I, Larhammer D, Beck-Sickinger AG. Novel analogues of neuropeptide Y with a preference for the Y1-receptor. Eur J Biochem 2001; 268:2828–2837.PubMedGoogle Scholar
  37. 37.
    Bernard BF, Béhé M, Breeman WAP, Nock B, Maecke HR, Schmitt J, Behr TM, Maina T, Waser B, Reubi J, Krenning EP, de Jong M. Preclinical evaluation of minigastrin analogs for CCK-B receptor targeting. Cancer Biother Radiopharm 2003; in press.Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Division of Cell Biology and Experimental Cancer Research, Institute of PathologyUniversity of BerneBerneSwitzerland

Personalised recommendations